PMC isochem

PMC Isochem is an established, revenue-generating private CDMO with a strong technological foundation in hazardous chemistry and polymer science for drug delivery. The company leverages a broad technology platform including phosgenation, biocatalysis, and specialized polymerization to serve pharmaceutical clients from development through commercial manufacturing. Its strategic expansion into CRO services and focus on innovative areas like polyamino acid-based drug delivery systems position it to capture growth in the advanced therapeutics market. With a long-standing operational history and a clear focus on complex chemistry, PMC Isochem is a specialized partner for pharmaceutical companies.

Specialized chemical synthesis (phosgenation, biocatalysis, hazardous reactions) and a proprietary polyamino acid polymer platform for drug delivery, based on Amino acid N-CarboxyAnhydride (NCA) chemistry.

PMC Isochem competes in the fragmented CDMO market, differentiating itself through niche expertise in hazardous chemistry and polyamino acid polymers. It faces competition from large, full-service CDMOs (e.g., Lonza, Catalent) and other specialized chemistry providers, but its specific polymer technology offers a unique value proposition in the drug delivery segment.